Stephen R Saklad, Tiffany-Jade Kreys, Stephanie V. Phan
{"title":"阿立哌唑长效注射(ABILIFY MAINTENA)治疗精神分裂症","authors":"Stephen R Saklad, Tiffany-Jade Kreys, Stephanie V. Phan","doi":"10.9740/MHC.2015.07.149","DOIUrl":null,"url":null,"abstract":"ABSTRACT Introduction: Patients with schizophrenia often relapse as a result of medication nonadherence. Methods: Long-acting injectable antipsychotics have been developed to improve medication adherence rates in this patient population. Results: Aripiprazole long-acting injection (LAI), branded Abilify Maintena®, received Food and Drug Administration approval for the treatment of schizophrenia in February of 2013. Aripiprazole LAI is the fourth intramuscular second-generation antipsychotic indicated for the treatment of schizophrenia. Discussion: This manuscript reviews important clinical information regarding its use as well as efficacy and tolerability data.","PeriodicalId":18691,"journal":{"name":"Mental Health Clinician","volume":"31 1","pages":"149-161"},"PeriodicalIF":0.0000,"publicationDate":"2015-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Aripiprazole long-acting injectable (ABILIFY MAINTENA) for treatment of schizophrenia\",\"authors\":\"Stephen R Saklad, Tiffany-Jade Kreys, Stephanie V. Phan\",\"doi\":\"10.9740/MHC.2015.07.149\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"ABSTRACT Introduction: Patients with schizophrenia often relapse as a result of medication nonadherence. Methods: Long-acting injectable antipsychotics have been developed to improve medication adherence rates in this patient population. Results: Aripiprazole long-acting injection (LAI), branded Abilify Maintena®, received Food and Drug Administration approval for the treatment of schizophrenia in February of 2013. Aripiprazole LAI is the fourth intramuscular second-generation antipsychotic indicated for the treatment of schizophrenia. Discussion: This manuscript reviews important clinical information regarding its use as well as efficacy and tolerability data.\",\"PeriodicalId\":18691,\"journal\":{\"name\":\"Mental Health Clinician\",\"volume\":\"31 1\",\"pages\":\"149-161\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Mental Health Clinician\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.9740/MHC.2015.07.149\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mental Health Clinician","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9740/MHC.2015.07.149","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Aripiprazole long-acting injectable (ABILIFY MAINTENA) for treatment of schizophrenia
ABSTRACT Introduction: Patients with schizophrenia often relapse as a result of medication nonadherence. Methods: Long-acting injectable antipsychotics have been developed to improve medication adherence rates in this patient population. Results: Aripiprazole long-acting injection (LAI), branded Abilify Maintena®, received Food and Drug Administration approval for the treatment of schizophrenia in February of 2013. Aripiprazole LAI is the fourth intramuscular second-generation antipsychotic indicated for the treatment of schizophrenia. Discussion: This manuscript reviews important clinical information regarding its use as well as efficacy and tolerability data.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
